Program
seltorexant
Also written as “JNJ-42847922”, “Seltorexant” and “JNJ-42847922, 5 mg”.
Its studies are mostly in Depressive Disorder, Major · Sleep Initiation and Maintenance Disorders · Alzheimer Disease · Sleep Apnea, Obstructive · Renal Insufficiency, led by Johnson & Johnson.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 332 open or running | phase 3since Aug 13, 2020 | Jan 22, 2014 | Dec 30, 2026phase 3 · NCT06559306 |
- Named in Johnson & Johnson’s own pipeline as
seltorexant
, phase 3, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Jan 22, 2014.
- Feb 8, 2018Phase 1 study in HealthyNCT03438461 · 49 enrolled · United States
- Apr 5, 2018Phase 1 study in HealthyNCT03494907 · 52 enrolled · Belgium
- Sep 21, 2018Phase 1 study in HealthyNCT03682380 · 151 enrolled · United States
- Jan 4, 2019Phase 1 study in Sleep Apnea, ObstructiveNCT03796026 · 34 enrolled · United States
- Jun 26, 2020Phase 1 study in Depressive Disorder, MajorNCT04451187 · 63 enrolled · Belgium, Germany
- Aug 13, 20203 phase 3 studies in Depressive Disorder, MajorNCT04513912, NCT04533529, NCT04532749
- Sep 14, 2020Phase 1 study in HealthyNCT04553042 · 69 enrolled · United States
- Nov 2, 2020Phase 1 study in Renal InsufficiencyNCT04616677 · 24 enrolled · United States
- Jun 30, 2021Phase 1 study in Depressive Disorder, MajorNCT04951609 · 31 enrolled · United States, Italy, Spain and more
- Jul 2, 2021Phase 1 study in HealthyNCT04960124 · 24 enrolled · Germany
- Feb 2, 2022Phase 1 study in HealthyNCT05236868 · 10 enrolled · Netherlands
- Mar 25, 2022Phase 2 study in Alzheimer DiseaseNCT05307692 · 88 enrolled · United States
- Aug 15, 2024Phase 3 study in Depressive Disorder, MajorNCT06559306 · 752 planned · United States, Argentina, Brazil and more
- May 1, 2026Phase 3 study in Depressive Disorder, MajorNCT07573176 · 600 planned · United States, Argentina, Brazil and more
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Depressive Disorder, MajorNCT06559306
- Aug 24, 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT07573176
TargetBeta
“Orexin receptor 2 antagonist”ChEMBL 37, by rule
Other programs on HCRTR2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| daridorexantrule | Idorsia Pharmaceuticals | phase 4 | 34 |
| HS-10506 | Hansoh Pharmaceutical Group | phase 3 | 6 |
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07573176Depressive Disorder, Major · United States, Argentina, Brazil and more | 3 | Recruiting | Aug 24, 2028 | 600 |
| NCT06559306Depressive Disorder, Major · United States, Argentina, Brazil and more | 3 | Recruiting | Dec 30, 2026 | 752 |
| NCT05307692Alzheimer Disease · United States | 2 | Completed | Nov 10, 2023 | 88 |
| NCT05236868Healthy · Netherlands | 1 | Completed | Mar 1, 2022 | 10 |
| NCT04960124Healthy · Germany | 1 | Completed | Nov 19, 2021 | 24 |
| NCT04951609Depressive Disorder, Major · United States, Italy, Spain and more | 1 | Terminated | Apr 8, 2024 | 31 |
| NCT04616677Renal Insufficiency · United States | 1 | Completed | Oct 18, 2022 | 24 |
| NCT04553042Healthy · United States | 1 | Completed | Dec 20, 2020 | 69 |
| NCT04532749Depressive Disorder, Major · United States, Argentina, Chile and more | 3 | Terminated | May 24, 2022 | 212 |
| NCT04533529Depressive Disorder, Major · United States, Brazil, Bulgaria and more | 3 | Completed | Apr 25, 2023 | 588 |
| NCT04513912Depressive Disorder, Major · United States, Argentina, Belgium and more | 3 | Completed | Oct 3, 2023 | 757 |
| NCT04451187Depressive Disorder, Major · Belgium, Germany | 1 | Completed | Mar 16, 2023 | 63 |
| NCT03796026Sleep Apnea, Obstructive · United States | 1 | Completed | Jun 7, 2019 | 34 |
| NCT03682380Healthy · United States | 1 | Completed | Aug 23, 2019 | 151 |
| NCT03494907Healthy · Belgium | 1 | Completed | Aug 13, 2018 | 52 |
| NCT03438461Healthy · United States | 1 | Completed | May 30, 2018 | 49 |
| NCT03374475Depressive Disorder, Major · United States, Belgium, Germany and more | 1 | Completed | Apr 29, 2019 | 140 |
| NCT03375203Sleep Initiation and Maintenance Disorders · United States, Belgium, France and more | 2 | Completed | Apr 3, 2019 | 365 |
| NCT03321526Depressive Disorder, Major · United States | 2 | Completed | Jun 13, 2019 | 107 |
| NCT03249402Healthy · Belgium | 1 | Completed | Nov 24, 2017 | 24 |
| NCT03227224Depressive Disorder, Major · United States, Bulgaria, Finland and more | 2 | Completed | Jan 12, 2019 | 287 |
| NCT03025022Healthy · United States | 1 | Completed | Feb 27, 2017 | 8 |
| NCT02837692Healthy · United States | 1 | Completed | Sep 7, 2017 | 140 |
| NCT02661893Healthy · United States | 1 | Completed | Feb 2016 | 14 |
| NCT02617810Healthy · United States | 1 | Completed | Feb 2016 | 18 |
| NCT02578472Healthy · Netherlands | 1 | Completed | Feb 2016 | 36 |
| NCT02555124Healthy · Japan | 1 | Completed | Oct 31, 2015 | 24 |
| NCT02475161Healthy · United States | 1 | Completed | Jul 2015 | 16 |
| NCT02464046Sleep Initiation and Maintenance Disorders · United States, Germany, Netherlands | 2 | Completed | Dec 2, 2015 | 28 |
| NCT02476058Depressive Disorder, Major · Belgium, Germany, Netherlands | 1 | Completed | Jan 4, 2016 | 48 |
| NCT02455856Healthy · Germany | 1 | Completed | Jun 19, 2015 | 16 |
| NCT02230878Healthy · Germany | 1 | Completed | Nov 2014 | 40 |
| NCT02067299Depressive Disorder, Major · Germany, Netherlands | 1 | Completed | Dec 2014 | 20 |
How it is read
Names in the registry
- “JNJ-42847922”, 13 entries
- “Seltorexant”, 10 entries
- “JNJ-42847922, 5 mg”, 2 entries
- “JNJ-42847922, 20 mg”, 2 entries
- “Seltorexant 40 mg”, 2 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 12 studies
- Sleep Initiation and Maintenance Disorders, 2 studies
- Alzheimer Disease, 1 study
- Sleep Apnea, Obstructive, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.